In real-world patients with mHSPC, a PSA cutoff of 0.2 ng/mL after 6 to 12 months of intensified hormone therapy predicts survival outcomes. An absolute PSA level of 0.2 ng/mL or more at 6 to 12 ...
Achieving a PSA nadir of less than 0.2 ng/mL is needed for optimal mCSPC outcomes. For real-world patients with metastatic castration-sensitive prostate cancer (mCSPC), reaching a PSA nadir less than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback